>
Switch to:

Orgenesis Total Liabilities

: $21.21 Mil (As of Dec. 2021)
View and export this data going back to 2010. Start your Free Trial

Orgenesis's Total Liabilities for the quarter that ended in Dec. 2021 was $21.21 Mil.

Orgenesis's quarterly Total Liabilities declined from Jun. 2021 ($24.06 Mil) to Sep. 2021 ($21.94 Mil) and declined from Sep. 2021 ($21.94 Mil) to Dec. 2021 ($21.21 Mil).

Orgenesis's annual Total Liabilities declined from Dec. 2019 ($86.42 Mil) to Dec. 2020 ($24.96 Mil) and declined from Dec. 2020 ($24.96 Mil) to Dec. 2021 ($21.21 Mil).

Orgenesis Total Liabilities Historical Data

The historical data trend for Orgenesis's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orgenesis Annual Data
Trend Nov12 Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Dec19 Dec20 Dec21
Total Liabilities
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.75 46.80 86.42 24.96 21.21

Orgenesis Quarterly Data
Feb17 May17 Aug17 Nov17 Feb18 May18 Aug18 Nov18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
Total Liabilities Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 24.96 27.36 24.06 21.94 21.21

Orgenesis Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Orgenesis's Total Liabilities for the fiscal year that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.365+(5.456+0.288
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.101)
=21.21

Total Liabilities=Total Assets (A: Dec. 2021 )-Total Equity (A: Dec. 2021 )
=59.841-38.631
=21.21

Orgenesis's Total Liabilities for the quarter that ended in Dec. 2021 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=15.365+(5.456+0.288
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit)
+0+0.101)
=21.21

Total Liabilities=Total Assets (Q: Dec. 2021 )-Total Equity (Q: Dec. 2021 )
=59.841-38.631
=21.21

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Orgenesis Total Liabilities Related Terms

Thank you for viewing the detailed overview of Orgenesis's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Orgenesis Business Description

Orgenesis logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Comparable Companies
NAS:CASI ROCO:6461 NAS:PRTG XKRX:291650 NAS:ENTX TSE:4588 OSTO:ACE NAS:EYEN TSX:ONC XKRX:072520
Traded in Other Exchanges
45O:Germany 45O:Germany
Address
20271 Goldenrod Lane, Germantown, MD, USA, 20876
Website
https://www.orgenesis.com
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
Executives
Sidransky David director JOHNS HOPKINS UNIVERSITY 720 RUTLAND AVENUE BALTIMORE MD 21205
Reithinger Neil officer: CFO, Treasurer and Secretary 14950 N. 83RD PLACE SUITE 1 SCOTTSDALE AZ 85260
Philips Mario director C/O ATMI, INC DANBURY CT 06810
Ferber Sarah officer: Chief Scientific Officer 17B HAHASKALA STREET TEL AVIV L3 67890
Yachin Guy director 7 ORCHARD WAY N POTOMAC MD 20854
Nanda Ashish director 2301, 23RD FLOOR, TIFFANY TOWERS CLUSTER W, JLT, DUBAI, UAE DUBAI C0 4452
Bedoret Denis officer: See Remarks 48, RUE AUGUSTE PICCARD GOSSELIES C9 6041
Universite Libre De Bruxelles other: less than 10% AVENUE F, ROOSEVELT, 50 BRUSSELS C9 1050
Theodorus Ii Sa other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Theodorus Sca other: less than 10% ALLEE DE LA RECHERCHE, 12 BRUSSELS C9 1070
Belenger Olivier other: less than 10% DIEWEG, 69 BRUSSELS C9 1070
Shvartz Oded 10 percent owner 130 BIRUINTEI BVD. PANTELIMON, ILFOV S5 0000000
Bultot Hugues director AVENUE DE L??HORIZON 24 WOLUWE SAINT PIERRE C9 1150
Buyse Chris Georges Frans director BAILLET LATOURLEI 119A BRUSSELS C9 2390
Tenne Joseph officer: CFO Treasurer Secretary 6225 NEIL ROAD, SUITE 300 C/O ORMAT TECHNOLOGIES, INC. RENO NV 89511

Orgenesis Headlines

From GuruFocus

Orgenesis CEO to Participate in Webinar Panel on "New Approaches to COVID-19" on Thursday, September 10th

By Marketwired 09-09-2020

Orgenesis Second Quarter 2020 Revenue Increases 55% Reflecting Progress of POCare Platform

By Marketwired 08-07-2020

Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing

By GuruFocusNews 01-18-2022

Orgenesis Enters Second Phase of Collaboration with Hospital Infantil Universitario Nio Jess in Madrid with Exclusive License to Commercialize Celyvir Solid Tumor Therapy

By Marketwired 03-11-2021

Orgenesis Completes Acquisition of Koligo Therapeutics and Announces Additional Acquisition of Icellator Technology from Tissue Genesis in Related Transaction

By Marketwired 10-19-2020

Orgenesis Schedules First Quarter 2021 Business Update Conference Call

By Marketwired 05-05-2021

FDA Approves Orgenesis IDE for Pilot Clinical Trial of its Tissue Genesis Icellator2 to Treat ARDS Resulting from COVID-19 Infection

By Marketwired 05-06-2021

Orgenesis Mobile Processing Units and Labs (OMPULs) to be Used for Point-of-Care Production and Commercialization of Cell and Gene Therapies in Collaboration with Dong-a University Hospital and Cure Therapeutics in South Korea

By Marketwired 03-08-2021

Orgenesis Announces Anti-Viral “BioShield” Program Designed to Potentially Increase Preparedness, Rapidly Address Virus Spread and Protect Against Future Outbreaks such as COVID-19

By Marketwired 06-10-2020

Orgenesis Selects Therapeutics, Inc. as CRO to Support Development and Planned Phase 2 Clinical Study of Ranpirnase for the Treatment of External Genital Warts

By Marketwired 08-20-2020

Other Sources

$ORGS - Orgenesis: A Cell And Gene Therapy Disruptor With A Nice Risk Reward Profile. Orgenesis Cell And Gene Therapy Disruptor Nice Risk Reward Profile

By Seekingalpha 2021-01-28

$ORGS - Orgenesis Inc. (ORGS) CEO Vered Caplan on Q3 2021 Results - Earnings Call Transcript.…

By Seekingalpha 2021-11-06

$ORGS - Orgenesis: A Mispriced Visionary In Cell And Gene Therapy Manufacturing. Orgenesis A Mispriced Biotech Visionary

By Seekingalpha 2021-05-17

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)